IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient trader: today\u2019s -7.11% selloff plus a worsening MACD momentum profile suggests near-term follow-through risk despite the longer-term bullish moving-average stack.", "Best \u201cbuy-now\u201d case is a support bounce: price (5.89) is only modestly above S1 support (5.647). If that level fails, the next notable support is near S2 (5.00), which makes chasing here unattractive.", "Options positioning is bullish (call-heavy put/call ratios), but implied volatility is very elevated, signaling event-risk/speculation rather than clean trend confidence.", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: no signal on given stock today.\n- SwingMax: No signal on given stock recently."]
["Trend mix: bullish moving averages (SMA_5 > SMA_20 > SMA_200) suggest the broader trend is still up, but the short-term momentum is deteriorating.", "MACD: histogram at -0.0282 (below zero) and negatively expanding = bearish momentum building after the drop.", "RSI(6): 50.775 (neutral) = not oversold; limited evidence that sellers are exhausted yet.", "Key levels: Pivot 6.693 is the near-term reclaim level; resistance above at R1 7.74. Support at S1 5.647 then S2 5.00. Current 5.89 is uncomfortably close to S1 after a heavy down day.", "Pattern-based stats provided: +1.07% next day / +4.23% next week, but -7.21% next month bias suggests rallies may fade rather than trend cleanly higher."]
launch of a mid-stage clinical study in indolent B-cell non-Hodgkin lymphoma (chemo-free combination approach) provides a tangible development catalyst.", "Analyst stance: Jefferies reiterated Buy and raised PT to $9 (from $8), framing the company as in \u201cexecution mode\u201d with potential regulatory/commercial expansion catalysts ahead.", "Derivatives sentiment: heavy call skew in both open interest and volume suggests traders are leaning bullish."]
["Price action: sharp -7.11% regular-session drop signals active selling pressure and weak near-term tape.", "Momentum: MACD histogram is negative and worsening, often consistent with continued downside/failed bounces in the immediate term.", "Near-term level risk: price is close to S1 (5.647); a break can quickly shift focus to ~5.00 (S2).", "Options volatility regime: very high IV/percentile implies elevated uncertainty; bullish option skew may be speculative rather than conviction buying.", "News feed quality: several listed items reference Oncolytics Biotech (not ImmunityBio), reducing confidence that today\u2019s newsflow is broadly supportive for IBRX specifically."]
["Latest quarter provided: 2025/Q3.", "Revenue growth: $32.061M, +425.07% YoY \u2192 strong top-line acceleration.", "Profitability: net income -$67.253M (down -21.55% YoY) and EPS -0.07 (down -41.67% YoY) \u2192 losses deepened despite revenue growth, implying continued cash burn/scale-up costs.", "Gross margin: 99.45% (down 0.55% YoY) \u2192 still extremely high, but the slight decline plus widening losses highlights that operating expenses are the main pressure point."]
["Most recent update provided (2025-12-12): Jefferies maintained a Buy and raised price target to $9 from $8.", "Wall Street pro view (pros): expanding commercial/regulatory footprint potential and pipeline advancement optionality (label/geography expansion narrative).", "Wall Street con view (cons): execution risk remains high (commercial rollout + clinical/regulatory milestones), and current financials still show sizable losses even with rapid revenue growth.", "Positioning/flows context: hedge funds and insiders reported as Neutral recently; no notable confirmation from insider accumulation.", "Influential/political trading: no recent congress trading data available (no signal from that channel)."]
